We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
FDA Accepts Bayer's Application for Label Expansion of Nubeqa
Read MoreHide Full Article
Bayer (BAYRY - Free Report) announced that the FDA has accepted its supplemental new drug application (sNDA) for Nubeqa (darolutamide).
The sNDA is seeking label expansion of Nubeqa in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC).
Year to date, shares of Bayer have lost 44.9% against the industry’s growth of 4.8%.
Image Source: Zacks Investment Research
Bayer’s Efforts to Expand Nubeqa’s Label
Nubeqa is an androgen receptor inhibitor (ARi) with a distinct chemical structure that competitively inhibits androgen binding, AR nuclear translocation and AR-mediated transcription.
The sNDA submitted is based on positive results from the late-stage ARANOTE study. Results showed that Nubeqa plus ADT significantly reduced the risk of progression or death in patients with metastatic mHSPC when compared to placebo plus ADT.
We note that Nubeqa is currently indicated for the treatment of adult patients with mHSPC in combination with docetaxel and for those with non-metastatic castration-resistant prostate cancer (nmCRPC).
A potential FDA approval of the sNDA will expand the indication for Nubeqa in patients with mHSPC to include Nubeqa both with and without chemotherapy.
BAYRY is also evaluating darolutamide across various stages of prostate cancer in a broad development program.
The program includes the phase III ARASTEP trial evaluating darolutamide plus ADT compared to ADT alone in hormone-sensitive high-risk biochemical recurrence (BCR) prostate cancer patients who have a positive PSMA PET/CT at baseline and no evidence of metastatic disease by conventional imaging.
Bayer is also evaluating darolutamide in the collaborative phase III DASL-HiCaP trial led by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. The study evaluates darolutamide as an adjuvant treatment for localized prostate cancer with a very high risk of recurrence.
Bayer’s Efforts to Strengthen Pharma Business
Bayer is looking to strengthen its pharmaceutical portfolio amid generic competition for Xarelto.
Nubeqa is one of Bayer's top drugs and a potential label expansion should further boost sales. The drug generated sales of more than €1 billion in the first nine months of 2024.
Bayer recently entered into a collaboration and license agreement with Cytokinetics (CYTK - Free Report) for the exclusive development and commercialization of aficamten in Japan.
Aficamten, a cardiac myosin inhibitor, is being evaluated for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy (HCM). As per the joint development plan, Bayer plans to conduct a phase III study in Japanese patients with obstructive HCM.
Bayer acquired marketing rights for the cardiovascular candidate, acoramidis, in Europe from BridgeBio.
A new drug application (NDA) for acoramidis has been filed with the FDA, and the regulatory body has set a target action date of Nov. 29, 2024, for the same.
BAYRY also submitted a Marketing Authorization Application (“MAA”) to the EMA for its pipeline candidate, elinzanetant.
The MAA is seeking approval of the candidate for the treatment of moderate to severe vasomotor symptoms (VMS, also known as hot flashes) associated with menopause or adjuvant endocrine therapy.
The FDA also accepted the company’s NDA for elinzanetant, seeking approval for the treatment of moderate-to-severe VMS.
Over the past 60 days, Pfizer’s earnings estimates have risen from $2.62 to $2.91 per share for 2024, while that for 2025 has increased from $2.85 to $2.92. PFE’s shares have lost 12.2% year to date.
Pfizer’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 74.50%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
FDA Accepts Bayer's Application for Label Expansion of Nubeqa
Bayer (BAYRY - Free Report) announced that the FDA has accepted its supplemental new drug application (sNDA) for Nubeqa (darolutamide).
The sNDA is seeking label expansion of Nubeqa in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC).
Year to date, shares of Bayer have lost 44.9% against the industry’s growth of 4.8%.
Image Source: Zacks Investment Research
Bayer’s Efforts to Expand Nubeqa’s Label
Nubeqa is an androgen receptor inhibitor (ARi) with a distinct chemical structure that competitively inhibits androgen binding, AR nuclear translocation and AR-mediated transcription.
The sNDA submitted is based on positive results from the late-stage ARANOTE study. Results showed that Nubeqa plus ADT significantly reduced the risk of progression or death in patients with metastatic mHSPC when compared to placebo plus ADT.
We note that Nubeqa is currently indicated for the treatment of adult patients with mHSPC in combination with docetaxel and for those with non-metastatic castration-resistant prostate cancer (nmCRPC).
A potential FDA approval of the sNDA will expand the indication for Nubeqa in patients with mHSPC to include Nubeqa both with and without chemotherapy.
BAYRY is also evaluating darolutamide across various stages of prostate cancer in a broad development program.
The program includes the phase III ARASTEP trial evaluating darolutamide plus ADT compared to ADT alone in hormone-sensitive high-risk biochemical recurrence (BCR) prostate cancer patients who have a positive PSMA PET/CT at baseline and no evidence of metastatic disease by conventional imaging.
Bayer is also evaluating darolutamide in the collaborative phase III DASL-HiCaP trial led by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. The study evaluates darolutamide as an adjuvant treatment for localized prostate cancer with a very high risk of recurrence.
Bayer’s Efforts to Strengthen Pharma Business
Bayer is looking to strengthen its pharmaceutical portfolio amid generic competition for Xarelto.
Nubeqa is one of Bayer's top drugs and a potential label expansion should further boost sales. The drug generated sales of more than €1 billion in the first nine months of 2024.
Bayer recently entered into a collaboration and license agreement with Cytokinetics (CYTK - Free Report) for the exclusive development and commercialization of aficamten in Japan.
Aficamten, a cardiac myosin inhibitor, is being evaluated for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy (HCM). As per the joint development plan, Bayer plans to conduct a phase III study in Japanese patients with obstructive HCM.
Bayer acquired marketing rights for the cardiovascular candidate, acoramidis, in Europe from BridgeBio.
A new drug application (NDA) for acoramidis has been filed with the FDA, and the regulatory body has set a target action date of Nov. 29, 2024, for the same.
BAYRY also submitted a Marketing Authorization Application (“MAA”) to the EMA for its pipeline candidate, elinzanetant.
The MAA is seeking approval of the candidate for the treatment of moderate to severe vasomotor symptoms (VMS, also known as hot flashes) associated with menopause or adjuvant endocrine therapy.
The FDA also accepted the company’s NDA for elinzanetant, seeking approval for the treatment of moderate-to-severe VMS.
BAYRY’s Zacks Rank & Stock to Consider
BAYRY currently carries a Zacks Rank #3 (Hold).
A better-ranked large-cap pharma stock is Pfizer (PFE - Free Report) , which currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Over the past 60 days, Pfizer’s earnings estimates have risen from $2.62 to $2.91 per share for 2024, while that for 2025 has increased from $2.85 to $2.92. PFE’s shares have lost 12.2% year to date.
Pfizer’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 74.50%.